They found that high expression levels of ERBB2 occurred in spheres showing hyperactive PI3K/AKT pathway and proved that triple targeting of ERBB2, MEK and PI3K induces CSC death and regression of anti-EGFR-resistant tumor xenografts, including those carrying KRAS and PIK3CA mutation[109]. This evidence concerns the gene EGFR and neoplasm.